Foundayo Pricing: April 2026
Foundayo (orforglipron) launched April 9, 2026 at $649/mo list price. LillyDirect self-pay from $149/mo. The only GLP-1 pill with no food restrictions.
Eli Lilly's Foundayo (orforglipron) is the newest GLP-1 on the market, FDA-approved April 1, 2026 and available since April 9. It's the only oral GLP-1 that can be taken any time of day without food or water restrictions — a major convenience advantage over oral Wegovy's empty-stomach requirement. Lilly priced the WAC at $649/month, roughly half of oral Wegovy's $1,349 WAC, and pre-stocked $1.5 billion worth of inventory to avoid the supply shortages that plagued earlier GLP-1 launches. Doses range from 0.8 mg to 17.2 mg (once daily).
LillyDirect Self-Pay
Eli Lilly's direct-to-consumer platform offers Foundayo at significantly below list price. Prescriptions were accepted immediately at launch, with shipping beginning April 6 and broad retail/telehealth availability by April 9.
| Channel | Price | Source |
|---|---|---|
| LillyDirect (Starting Dose) | $149/mo | Eli Lilly PR |
| LillyDirect (Maintenance Dose) | ~$349/mo | Drugs.com |
Insurance & Savings Card
Foundayo is covered by many commercial insurance plans at launch. Lilly's savings card brings out-of-pocket costs down significantly for insured patients.
| Channel | Price | Source |
|---|---|---|
| Commercial Insurance + Savings Card | As low as $25/mo | Eli Lilly PR |
| List Price (WAC) | $649/mo | GoodRx |
Government Programs
Foundayo is part of the Trump administration's MFN pricing framework for oral GLP-1 drugs. Medicare Part D coverage begins July 1, 2026.
| Channel | Price | Source |
|---|---|---|
| TrumpRx (Oral GLP-1) | $150/mo | AMCP |
| Medicare Part D (Starting July 2026) | $50/mo copay | Eli Lilly PR |